Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Agile Therapeutics, Inc. - Common Stock
(NQ:
AGRX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Mar 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Agile Therapeutics, Inc. - Common Stock
< Previous
1
2
Next >
Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 15, 2024
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
March 28, 2024
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Agile Therapeutics Announces Delisting from Nasdaq
March 25, 2024
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024
March 21, 2024
Live Conference Call and Webcast at 8:30 a.m. ET
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024
March 20, 2024
Live Conference Call and Webcast at 8:30 a.m. ET
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution
March 13, 2024
Elimination of Remaining Debt to Perceptive Advisors Leaves the Company’s Balance Sheet Debt Free
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
February 22, 2024
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement & Provides Performance Update
February 15, 2024
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
The Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without Cost
January 23, 2024
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Agile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act’s No-Cost Contraceptive Coverage Requirement
December 12, 2023
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Agile Therapeutics Posts Growth In Third Quarter Results, Reiterates Confidence In Target of $25M Net Revenue, Positive Cash Flow In 2024
November 22, 2023
Via
ACCESSWIRE
Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 09, 2023
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Agile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023
October 26, 2023
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2023
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Agile Therapeutics (NASDAQ: AGRX) Upgraded To “Buy” Rating By Analysts At Maxim Group
September 28, 2023
Via
ACCESSWIRE
Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Agile Says It's On Track To Hit $25-$30 Million Net Annual Revenue After A Strong Performance In Its Second Quarter
August 17, 2023
Via
ACCESSWIRE
Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 09, 2023
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Agile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023
July 26, 2023
Live Conference Call and Webcast at 8:30 a.m. ET
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
This Reproductive Health Company's Weekly Contraceptive Patch Can Reach Millions of Women Thanks to a Partnership With Afaxys
July 19, 2023
Via
ACCESSWIRE
Agile Therapeutics Partners With Telehealth Platforms To Expand Access To Weekly Birth Control Patch To Millions Of Women
July 18, 2023
Via
ACCESSWIRE
Agile Sees Renewed Hope For Even Broader Adoption Of Its Weekly Birth Control Patch After Biden’s Latest Executive Order Expanding Contraceptive Coverage
July 11, 2023
Via
ACCESSWIRE
H.C. Wainwright Reiterates Buy Rating For Agile Therapeutics (NASDAQ: AGRX), Citing Growing Demand For Twirla, A Weekly Low Dose Birth Control Patch
July 05, 2023
Via
ACCESSWIRE
This Women's Healthcare Company Raised $7.5 Million In A Public Offering And Says It's Targeting $25 To $30 Million Net Revenue By End Of 2023
July 03, 2023
Via
ACCESSWIRE
Agile Therapeutics Expects Its Innovative Once-A-Week Birth Control Patch To Drive Revenues Of $25-30 Million In 2023 - What Is The Hype All About?
June 30, 2023
Via
ACCESSWIRE
The Overturning of Roe v. Wade Has Changed the Landscape of Birth Control; Smaller Companies are now an Integral Part of Care
June 28, 2023
Via
ACCESSWIRE
Agile Therapeutics Announces the Availability of Twirla® to MMCAP Infuse Members
June 26, 2023
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Agile Therapeutics Commends the Biden Administration’s Commitment to Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services
June 23, 2023
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Agile Therapeutics Announces the Availability of Twirla® through FPA Women’s Health
June 15, 2023
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
Agile Therapeutics Announces New Agreement with vitaCare® Prescription Services to Improve Access to Twirla®
June 13, 2023
From
Agile Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
